NRX PHARMACEUTICALS INC logo

NRXP

NRX PHARMACEUTICALS INC

$1.38

Earnings Summary

Net Profits
$0.06Mn

Highlights

Net Profits:

NRX PHARMACEUTICALS INC’s net profit jumped 110.78% since last year same period to $0.06Mn in the Q3 2019. On a quarterly growth basis, NRX PHARMACEUTICALS INC has generated -66.37% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the NRX PHARMACEUTICALS INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.07
EPS Estimate Current Year
-0.07

Highlights

EPS Estimate Current Quarter:

NRX PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -0.07 - a 12.5% jump from last quarter’s estimates.

EPS Estimate Current Year:

NRX PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -0.07.

Key Ratios

Key ratios of the NRX PHARMACEUTICALS INC post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

NRX PHARMACEUTICALS INC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the NRX PHARMACEUTICALS INC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-03-01
-0.07
0
100%
2022-08-15
-0.1
-0.11
-10%
2022-11-14
-0.08
0
100%

Company Information

NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.

Organisation
NRX PHARMACEUTICALS INC
Headquarters
1201 Orange Street, Wilmington, DE, United States, 19801
Employees
0
Industry
Healthcare

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*